Reyon Pharmaceutical KRX:102460KOSPI
이연제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days4
Articles tracked6since Sep 11
In Q2 2026, Reyon Pharmaceutical reported revenue of ₩35.8bn, down 4.9% year on year, and an operating loss of ₩7.0bn. Reyon Pharmaceutical (이연제약) appeared in 0 Korean news articles and 4 DART filings over the past seven days. Coverage peaked on Oct 20 with 1 article.
Filing signals New 5% holder Major holder adding Dilution risk 4 quarters of losses Share pledge Screener
Reyon Pharmaceutical quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩35.8bn | -4.9% | −₩7.0bn margin −19.5% | −₩6.8bn |
| Q1 2026 | ₩36.1bn | -1.9% | −₩6.7bn margin −18.5% | −₩10.7bn |
| Q4 2025 derived | ₩33.9bn | -9.2% | −₩8.2bn margin −24.1% | −₩12.8bn |
| Q3 2025 | ₩37.6bn | -1.9% | −₩7.2bn margin −19.2% | −₩3.9bn |
| Q2 2025 | ₩37.7bn | +5.6% | −₩11.1bn margin −29.4% | −₩13.1bn |
| Q1 2025 | ₩36.8bn | -0.7% | −₩3.8bn margin −10.4% | ₩216m |
| Q4 2024 derived | ₩37.3bn | -4.0% | −₩3.0bn margin −8.1% | ₩2.5bn |
| Q3 2024 | ₩38.3bn | +2.3% | ₩1.7bn margin 4.3% | ₩619m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Reyon Pharmaceutical top stories 2 weeks, by number of outlets
- 1
- 2